Table 1. Baseline clinical and biological characteristics.
| Clinical or biological characteristic | HPD (n = 22) N (%) | Non-HPD (n = 98) N (%) | P |
|---|---|---|---|
| Neutrophil-to-lymphocyte ratio | 0.04 | ||
| High | 13 (59) | 48 (48) | |
| Low/Intermediate | 7 (32) | 49 (49) | |
| Unknown | 2 (9) | 1 (1) | |
| Antibiotic use | 0.07 | ||
| Yes | 5 (23) | 15 (15) | |
| No | 16 (73) | 83 (85) | |
| Unknown | 1 (4) | 0 (0) | |
| PDL1 status | 0.9 | ||
| Negative | 4 (18) | 16 (16) | |
| Positive | 10 (46) | 42 (43) | |
| Unknown | 8 (36) | 40 (41) | |
| Checkpoint inhibitor | 0.62 | ||
| PD1 based | 14 (64) | 68 (69) | |
| PDL1 based | 8 (36) | 30 (31) | |
| Checkpoint inhibition regimen | 1.0 | ||
| Monotherapy | 6 (27) | 26 (27) | |
| Combination | 16 (73) | 72 (73) | |
| Immunotherapy line | 0.16 | ||
| 1st line | 7 (22) | 48 (49) | |
| ≥ 2nd line | 15 (68) | 50 (51) | |
| Age | 0.35 | ||
| ≥ 65 years | 8 (36) | 47 (48) | |
| < 65 years | 14 (64) | 51 (52) | |
| Previous radiation therapy | 0.51 | ||
| No | 4 (18) | 13 (13) | |
| Yes | 18 (82) | 85 (87) | |
| Human papillomavirus | 0.82 | ||
| Negative | 12 (55) | 46 (47) | |
| Positive | 2 (9) | 10 (10) | |
| Unknown | 8 (36) | 42 (43) | |
| Performance status | 0.45 | ||
| 0 | 4 (18) | 31 (32) | |
| 1 | 17 (77) | 64 (65) | |
| ≥ 2 | 1 (5) | 3 (3) | |
| Gender | 1.0 | ||
| Male | 18 (82) | 79 (81) | |
| Female | 4 (18) | 19 (19) | |
| Smoking status | 0.75 | ||
| Non-smoker | 4 (18) | 15 (15) | |
| Previous/current smoker | 18 (82) | 83 (85) |
Abbreviation: HPD, hyperprogressive disease.